Radiotherapy with and without Fluorouracil for Lung Cancer
Author Information
Author(s): D Ball, J Smith, J Bishop, I Olver, S Davis, P O'Brien, D Bernshaw, G Ryan, M Millward
Primary Institution: Peter MacCallum Cancer Institute
Hypothesis
Does adding continuous-infusion fluorouracil to palliative thoracic radiation therapy improve symptom relief in patients with advanced non-small-cell lung cancer?
Conclusion
Adding fluorouracil to radiation therapy increased response rates but did not improve symptom relief or survival, and it resulted in more toxicity.
Supporting Evidence
- Overall response rate was higher in patients receiving fluorouracil (29%) compared to radiation alone (16%).
- Patients receiving fluorouracil experienced significantly more acute toxicities, including nausea and vomiting, oesophagitis, stomatitis, and skin reactions.
- Despite higher response rates, there were no significant differences in overall or progression-free survival between the two treatment arms.
Takeaway
Doctors wanted to see if a medicine called fluorouracil could help people feel better when combined with radiation for lung cancer, but it made them feel worse instead.
Methodology
Patients were randomized to receive either radiation therapy alone or radiation therapy with continuous infusion of fluorouracil, and their responses and toxicities were compared.
Potential Biases
Potential bias due to the non-blinded nature of the trial.
Limitations
The study did not include a chemotherapy-only arm, limiting conclusions about the interaction between fluorouracil and radiation.
Participant Demographics
Patients had advanced non-small-cell lung cancer, with a mix of squamous and non-squamous histologies.
Statistical Information
P-Value
0.035
Confidence Interval
95% CI 21-39%
Statistical Significance
p=0.035
Want to read the original?
Access the complete publication on the publisher's website